160
Participants
Start Date
July 3, 2023
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2030
Darovasertib
Oral, potent, selective inhibitor of Protein Kinase C
RECRUITING
St. Vincent's Health Sydney, Sydney
RECRUITING
Alfred Health, Melbourne
RECRUITING
Northwell, Manhasset
RECRUITING
Charité - Universitätsmedizin Berlin, Berlin
RECRUITING
Thomas Jefferson University, Philadelphia
RECRUITING
Fondazione IRCCS Istituto Nazionale Tumori, Milan
WITHDRAWN
Duke University Health System, Durham
RECRUITING
University of Miami, Miami
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
The Cancer and Hematology Centers, Grand Rapids
RECRUITING
Mayo Clinic Rochester, Rochester
RECRUITING
Institute Curie, Paris
RECRUITING
University of Texas Southwestern Medical Center, Dallas
NOT_YET_RECRUITING
Instituto Nazionale Tumori IRCCS - Fondazione Pascale, Napoli
RECRUITING
Sarah Cannon Research Institute, Denver
RECRUITING
HonorHealth Research Institute, Scottsdale
RECRUITING
UCLA Medical Center, Los Angeles
RECRUITING
Moores Cancer Center, La Jolla
RECRUITING
Stanford Cancer Institute, Palo Alto
RECRUITING
Princess Margaret Cancer Centre, Toronto
RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
RECRUITING
Leiden University Medical Center, Leiden
NOT_YET_RECRUITING
University College London Hospital - NHS Foundation Trust, London
NOT_YET_RECRUITING
The Clatterbridge Cancer Centre NHS Foundation Trust, Metropolitan Borough of Wirral
Lead Sponsor
IDEAYA Biosciences
INDUSTRY